The biological properties (NRF2 activation,selective QR2 inhibition,selective and reversible MAO-B inhibition, the best behavior in promotingdifferent neurogenic processes) and drug-like profile (positive invitro CNS permeability, good physiological solubility, no glutathioneconjugation, absence of PAINS, or Lipinski alerts) allowed us to select5-[(E)-2-(4-methoxyphenyl)ethenyl]-3-(prop-2-yn-1-yl)-1,3,4-oxadiazol-2(3H)-one (4e) for tissue AD models. Here, NFE2L2 is linked to Alzheimer disease.